Coherus Biosciences Inc

NASDAQ:CHRS   3:59:52 PM EDT
17.57
+1.54 (+9.61%)
Products, Regulatory

Coherus Biosciences Announces Positive Interim Results Of Choice-01, A Phase 3 Clinical Trial Evaluating Toripalimab In Combination With Chemotherapy

Published: 08/18/2021 23:46 GMT
Coherus Biosciences Inc (CHRS) - Announce Positive Interim Results of Choice-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination With Chemotherapy As First-line Treatment for Non-small Cell Lung Cancer.
Data Support Use of Toripalimab With Chemotherapy As First-line Therapy for Patients With Nsclc.
Toripalimab Plus Chemotherapy Met Primary Endpoint With Significant Improvement in Pfs Compared to Chemotherapy Alone.